GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GeneDx launched a new online offering to provide clinician-guided exome testing for children with global developmental delay, intellectual disability, or epilepsy. This digital channel allows families to initiate testing directly via GeneDx.com, bypassing traditional specialist referral wait times which can exceed six months for many pediatric patients. The launch aligns with updated American Academy of Pediatrics guidance recommending exome sequencing as a first-tier test, targeting a U.S.
Key figures
- Id patient population
- more than 1 million
- Waitlist gt 1yr percent
- about 25%
- Waitlist gt 6mo percent
- about 50%
- Diseases diagnosed count
- 4800
- Epilepsy patient population
- over 450,000
- Research publications count
- 1000
- Genetic causes estimate percent
- up to 50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.